TABLE 2.
Populationa | Assay results |
Sensitivity (95% CI) |
Specificity (95% CI) |
||||||
---|---|---|---|---|---|---|---|---|---|
Treponemal onlyb |
Test panel consensusc |
Treponemal only | Test panel consensusc | Treponemal only | Test panel consensusc | ||||
SHC | TR+ | TR− | TR+/NTR+ | TR−/NTR− | |||||
Age (yrs) | |||||||||
11–20 | + | 181 | 4 | 141 | 4 | 0.896 (0.845, 0.934) | 0.972 (0.931, 0.992) | 0.927 (0.824, 0.980) | 0.922 (0.811, 0.978) |
− | 21 | 51 | 4 | 47 | |||||
21–30 | + | 134 | 3 | 103 | 3 | 0.843 (0.777, 0.896) | 0.963 (0.907, 0.990) | 0.880 (0.688, 0.975) | 0.875 (0.676, 0.973) |
− | 25 | 22 | 4 | 21 | |||||
≤31 | + | 191 | 34 | 166 | 33 | 0.917 (0.877, 0.947) | 0.946 (0.910, 0.971) | 0.933 (0.908, 0.953) | 0.934 (0.909, 0.954) |
− | 18 | 474 | 9 | 468 | |||||
Sex | |||||||||
Female | + | 182 | 10 | 119 | 10 | 0.831 (0.775, 0.878) | 0.937 (0.880, 0.972) | 0.926 (0.868, 0.964) | 0.924 (0.865, 0.963) |
− | 37 | 125 | 8 | 122 | |||||
Male | + | 301 | 1 | 269 | 0 | 0.907 (0.870, 0.936) | 0.968 (0.939, 0.985) | 0.900 (0.555, 0.997) | 1.000 (0.478, 1.000) |
− | 31 | 9 | 9 | 5 | |||||
Pregnancy status | |||||||||
Nonpregnant | + | 46 | 0 | 42 | 0 | 0.780 (0.653, 0.877) | 0.875 (0.749, 0.953) | 1.000 (0.478, 1.000) | 1.000 (0.292, 1.000) |
− | 13 | 5 | 6 | 3 | |||||
Pregnant | + | 96 | 10 | 39 | 10 | 0.814 (0.731, 0.879) | 0.951 (0.835, 0.994) | 0.923 (0.863, 0.962) | 0.922 (0.862, 0.962) |
− | 22 | 120 | 2 | 119 | |||||
HIV positive | + | 18 | 4 | 3 | 4 | 0.667 (0.460, 0.835) | 0.600 (0.147, 0.947) | 0.923 (0.815, 0.973) | 0.922 (0.811, 0.978) |
− | 9 | 48 | 2 | 47 |
A total of 1,406 sample results were stratified based on age, sex, pregnancy, and HIV status. Populations may overlap across categories. For a given category, not all information was available for the remaining categories.
TR assays include TP-PA, EIA, and CIA platforms.
Test panel consensus refers to results that were either reactive by both treponemal and nontreponemal (RPR) tests or nonreactive by both treponemal and nontreponemal tests; discordant treponemal and nontreponemal results were excluded from analysis.